Artelo, a US-listed pharmaceutical company, announced the launch of its Solana reserve asset strategy.

This article is machine translated
Show original

On August 4, Artelo Biosciences (NASDAQ ticker: ARTL) announced the completion of a $9.475 million over-the-counter private placement, which will be used to launch a digital asset reserve strategy centered on Solana (SOL), becoming the first listed pharmaceutical company to include SOL in its reserve assets.

This private placement includes the issuance of common stock (or prepaid warrants) at a price of $10.45 per share, as well as two batches of three-year warrants with exercise prices of $10.20 and $50, respectively. The transaction is expected to be completed on August 5, 2025.

Source
Disclaimer: The content above is only the author's opinion which does not represent any position of Followin, and is not intended as, and shall not be understood or construed as, investment advice from Followin.
Like
Add to Favorites
Comments